1,240 reports of this reaction
4.4% of all LEDIPASVIR AND SOFOSBUVIR reports
#3 most reported adverse reaction
NAUSEA is the #3 most commonly reported adverse reaction for LEDIPASVIR AND SOFOSBUVIR, manufactured by Gilead Sciences, Inc. There are 1,240 FDA adverse event reports linking LEDIPASVIR AND SOFOSBUVIR to NAUSEA. This represents approximately 4.4% of all 27,933 adverse event reports for this drug.
Patients taking LEDIPASVIR AND SOFOSBUVIR who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among LEDIPASVIR AND SOFOSBUVIR users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for LEDIPASVIR AND SOFOSBUVIR:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,240 FDA reports for LEDIPASVIR AND SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 4.4% of all adverse event reports for LEDIPASVIR AND SOFOSBUVIR, making it one of the most commonly reported side effect.
If you experience nausea while taking LEDIPASVIR AND SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.